Subscribe To

Price Alert Latest News Economic Calendar News

CDXC / ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China

ChromaDex Corp (NASDAQ: CDXC) has agreed to establish a joint venture through its wholly-owned subsidiary ChromaDex Asia Limited. ChromaDex Asia is expected to assume the distribution agreement with Sinopharm Xingsha relating to the commercialization of Tru. Read More

Demo Live Account See Partner Details

Content Topics

Chromadex

Establishes

Joint

Venture

Niagen

Distribution

Stock

CDXC

Posted: May 20 2022, 10:06

Author Name: Benzinga

CDXC News

By Business Wire
October 31, 2023

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy

By Seeking Alpha
August 9, 2023

ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript

ChromaDex Corporation (NASDAQ:CDXC ) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media

By Business Wire
August 2, 2023

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced th

By Business Wire
May 2, 2023

ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Q1Earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy

By Seeking Alpha
March 8, 2023

ChromaDex Corporation (CDXC) Q4 2022 Earnings Call Transcript

ChromaDex Corporation (NASDAQ:CDXC ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors,

By Zacks Investment Research
March 8, 2023

ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold

By Business Wire
February 27, 2023

ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy

By Zacks Investment Research
December 19, 2022

Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for ChromaDex (CDXC) as it is technically in oversold territory now. In addition to this technical mea

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.